

# Peter Kolkhof

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8820821/publications.pdf>

Version: 2024-02-01

57  
papers

7,114  
citations

87723

38  
h-index

149479

56  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2992  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.   | 0.4  | 50        |
| 2  | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.   | 1.0  | 341       |
| 3  | Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.   | 3.0  | 89        |
| 4  | Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3220-3234.  | 2.7  | 65        |
| 5  | Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.  | 1.6  | 86        |
| 6  | Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.                                 | 2.9  | 23        |
| 7  | Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.  | 2.6  | 112       |
| 8  | Finerenone Reduces Renal ROR $\gamma$ t <sup>+</sup> T Cells and Protects against Cardiorenal Damage. <i>American Journal of Nephrology</i> , 2022, 53, 552-564.   | 1.4  | 6         |
| 9  | Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.   | 1.6  | 171       |
| 10 | Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.  | 0.7  | 17        |
| 11 | Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.   | 1.0  | 249       |
| 12 | Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. <i>FASEB Journal</i> , 2021, 35, e21314.   | 0.2  | 12        |
| 13 | Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. <i>American Journal of Nephrology</i> , 2021, 52, 588-601.                      | 1.4  | 31        |
| 14 | Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. <i>American Journal of Nephrology</i> , 2021, 52, 642-652.  | 1.4  | 80        |
| 15 | Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.  | 1.2  | 74        |
| 16 | Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.  | 13.9 | 599       |
| 17 | Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders â New perspectives for combination therapy. <i>Pharmacological Research</i> , 2021, 172, 105859.   | 3.1  | 37        |
| 18 | Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1141-1157. | 1.9  | 26        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. <i>FASEB Journal</i> , 2020, 34, 12450-12465.                       | 0.2  | 38        |
| 20 | Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.   | 13.9 | 1,148     |
| 21 | Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. <i>European Journal of Heart Failure</i> , 2020, 23, 743-750.                                      | 2.9  | 16        |
| 22 | Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. <i>ESC Heart Failure</i> , 2020, 7, 3983-3995.  | 1.4  | 13        |
| 23 | The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. <i>Biochemical Pharmacology</i> , 2019, 168, 173-183.   | 2.0  | 33        |
| 24 | Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.                                  | 1.4  | 127       |
| 25 | Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.                                  | 1.4  | 112       |
| 26 | Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 44-52. | 0.8  | 8         |
| 27 | Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. <i>Hypertension</i> , 2018, 71, 599-608.   | 1.3  | 149       |
| 28 | The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. <i>Kidney International</i> , 2018, 93, 1344-1355.                             | 2.6  | 109       |
| 29 | Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. <i>Frontiers in Pharmacology</i> , 2018, 9, 1131.  | 1.6  | 61        |
| 30 | Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1546-1555.                            | 1.7  | 44        |
| 31 | Corticosteroid receptors adopt distinct cyclical transcriptional signatures. <i>FASEB Journal</i> , 2018, 32, 5626-5639.   | 0.2  | 22        |
| 32 | Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 124-133.  | 0.9  | 32        |
| 33 | Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2399-2407.  | 2.2  | 36        |
| 34 | Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1216-1226.  | 3.0  | 68        |
| 35 | 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. <i>Journal of Endocrinology</i> , 2017, 234, T125-T140.  | 1.2  | 174       |
| 36 | Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 870-878.   | 1.3  | 92        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NF- $\kappa$ B Pathway. <i>Hypertension</i> , 2017, 70, 1148-1156.   | 1.3 | 67        |
| 38 | The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. <i>PLoS ONE</i> , 2017, 12, e0184888.  | 1.1 | 34        |
| 39 | Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 402-411.   | 0.8 | 59        |
| 40 | A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. <i>Circulation Journal</i> , 2016, 80, 1113-1122.  | 0.7 | 54        |
| 41 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.   | 1.0 | 274       |
| 42 | Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 271-305.   | 0.9 | 102       |
| 43 | Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. <i>Hypertension</i> , 2016, 67, 717-723.  | 1.3 | 69        |
| 44 | Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 398-404.                                   | 3.0 | 50        |
| 45 | Abstract 055: Benefit of Mineralocorticoid Receptor Antagonism in Acute Kidney Injury: Role of Smooth Muscle Rac1. <i>Hypertension</i> , 2016, 68, .  | 1.3 | 0         |
| 46 | Abstract P298: Finerenone Protects Against the Acute and Chronic Consequences of Renal Ischemia/reperfusion Injury. <i>Hypertension</i> , 2016, 68, .   | 1.3 | 0         |
| 47 | Nonsteroidal antagonists of the mineralocorticoid receptor. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 417-424.  | 1.0 | 100       |
| 48 | Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. <i>Journal of Biological Chemistry</i> , 2015, 290, 21876-21889.  | 1.6 | 116       |
| 49 | Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.  | 3.8 | 523       |
| 50 | Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628. <i>PLoS ONE</i> , 2015, 10, e0145666.   | 1.1 | 12        |
| 51 | Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 69-78.   | 0.8 | 265       |
| 52 | Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463. | 1.0 | 419       |
| 53 | Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.   | 2.9 | 72        |
| 54 | Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases. <i>ChemMedChem</i> , 2012, 7, 1385-1403.   | 1.6 | 194       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. <i>Molecular and Cellular Endocrinology</i> , 2012, 350, 310-317.         | 1.6 | 129       |
| 56 | Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. <i>FASEB Journal</i> , 2011, 25, 968-978.                                   | 0.2 | 65        |
| 57 | A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule. <i>Journal of Biological Chemistry</i> , 2010, 285, 29932-29940. | 1.6 | 157       |